ArticleThe Lancet. Oncology2018

Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.

Bo Jan Noordman et al.PubMed ↗Publisher ↗

No numbers read from the abstract.